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To investigate the use of repurposed and adjuvant 
drugs in patients admitted to hospital with covid-19 
across three continents.
Design
Multinational network cohort study.
setting
Hospital electronic health records from the United 
States, Spain, and China, and nationwide claims data 
from South Korea.
ParticiPants
303 264 patients admitted to hospital with covid-19 
from January 2020 to December 2020.
Main OutcOMe Measures
Prescriptions or dispensations of any drug on or 30 
days after the date of hospital admission for covid-19.
results
Of the 303 264 patients included, 290 131 were from 
the US, 7599 from South Korea, 5230 from Spain, and 
304 from China. 3455 drugs were identified. Common 
repurposed drugs were hydroxychloroquine (used 
in from <5 (<2%) patients in China to 2165 (85.1%) 
in Spain), azithromycin (from 15 (4.9%) in China to 
1473 (57.9%) in Spain), combined lopinavir and 
ritonavir (from 156 (<2%) in the VA-OMOP US to 2,652 
(34.9%) in South Korea and 1285 (50.5%) in Spain), 
and umifenovir (0% in the US, South Korea, and Spain 
and 238 (78.3%) in China). Use of adjunctive drugs 
varied greatly, with the five most used treatments 
being enoxaparin, fluoroquinolones, ceftriaxone, 
vitamin D, and corticosteroids. Hydroxychloroquine 
use increased rapidly from March to April 2020 but 
declined steeply in May to June and remained low for 
the rest of the year. The use of dexamethasone and 
corticosteroids increased steadily during 2020.
cOnclusiOns
Multiple drugs were used in the first few months of 
the covid-19 pandemic, with substantial geographical 
and temporal variation. Hydroxychloroquine, 
azithromycin, lopinavir-ritonavir, and umifenovir (in 
China only) were the most prescribed repurposed 
drugs. Antithrombotics, antibiotics, H2 receptor 
antagonists, and corticosteroids were often used as 
adjunctive treatments. Research is needed on the 
comparative risk and benefit of these treatments in 
the management of covid-19.
Introduction
By the end of 2020, more than 85 million confirmed 
cases of covid-19 and almost 2 000 000 related deaths 
occurred worldwide.1 Despite a lack of evidence on 
effectiveness, several medicines were repurposed in 
the first few months of the pandemic on the basis of in 
vitro antiviral activity.2
For the purpose of illustration, the US Food and 
Drug Administration gave emergency approval for 
use of hydroxychloroquine on 28 March 2020 but 
revoked this on 15 June 20203 and the Recovery and 
Solidarity trials also found little benefit associated 
with hydroxychloroquine use.4 5 Remdesivir was also 
proposed as treatment for covid-19 after showing 
in vitro antiviral activity against SARS-CoV-2.2 An 
international placebo controlled randomised con-
trolled trial showed a decrease in time to recovery.6 The 
Solidarity trial, however, suggested that remdesivir 
has no benefit on mortality, need for mechanical 
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WhAt Is AlreAdy knoWn on thIs topIc
Repurposed drugs are commonly used to manage novel diseases and conditions 
with no available treatments
Hydroxychloroquine was widely used to treat patients with covid-19 during the 
early phases of the pandemic
At the start of the pandemic, guidelines recommended concomitant treatments, 
including immune based drugs, antithrombotics, and antibiotics
WhAt thIs study Adds
The use of repurposed drugs to manage patients with covid-19 varied widely 
in the US, South Korea, Spain, and China during 2020 and a wide range of 
adjunctive treatments were used
Emerging clinical data highlighting concerns about the safety and efficacy of 
hydroxychloroquine and azithromycin affected use both geographically and 
temporally
The use of corticosteroids during 2020, however, steadily increased, with little 
use in the early stages of the pandemic (February to April)
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ventilation, and duration of hospital stay.5 Other 
drugs, such as interferon and lopinavir combined with 
ritonavir have also been shown to be ineffective.5 7
In the absence of approved antivirals for the 
treatment of covid-19, the cornerstone of management 
has been supportive care, with adjunctive treatments 
playing a major role. The two recognised drug classes 
used for adjunctive treatment are corticosteroids and 
anticytokines (eg, tocilizumab). A large randomised 
controlled trial and meta-analysis showed that the 
glucocorticosteroid dexamethasone and corticoste-
roids reduced mortality among patients receiving 
mechanical ventilation or oxygen.8 9 Tocilizumab was 
found to significantly reduce mortality in patients 
admitted to hospital with covid-19.10 Although 
additional adjunctive treatments are recognised in 
2020 guidelines, including antithrombotics, statins, 
and antihypertensives,11-15 recommendations for 
covid-19 treatment in clinical guidelines have varied 
both geographically and temporally.16
Regulators and public health agencies need to keep 
up with trends in covid-19 clinical practice. Tweets 
and press conferences have been shown to influence 
entire practice patterns but based on little evidence 
for the utility of treatments. Although attention has 
shifted to vaccine surveillance since December 2020, 
there is still a need to understand what treatments are 
effective for individual patients and at what harm This 
body of evidence is critical for comparative purposes 
as more data become available during the pandemic. 
With known problems in the supply chain for certain 
drugs, an understanding of what drugs are being used 
to treat covid-19 at different stages of the disease could 
help resource constrained environments.
We investigated the use of repurposed and adjunctive 
drugs among patients admitted to hospital with 
covid-19 and among patients receiving intensive care 
in the United States, South Korea, Spain, and China.
Methods
This multinational network cohort study was based on 
hospital electronic health records and claims data. We 
mapped data from different sites to the Observational 
Medical Outcomes Partnership (OMOP) Common Data 
Model (CDM).17 This approach allowed contributing 
centres to execute analytical code in a distributed or 
federated fashion, where each site runs the analyses 
separately in-house and returns a results dataset 
without sharing patient level data. The study protocol 
and analytical package were released on 11 June 2020, 
and iterative updates are continually released through 
GitHub.18 Our study was also published as a preprint.19
Data sources
Data were obtained from the US, South Korea, Spain, 
and China. Electronic health record data from the US 
were obtained from Columbia University Irving Medical 
Center (CUIMC, February to December 2020), IQVIA 
Hospital CDM (February to October 2020), STAnford 
medicine Research data Repository (STARR-OMOP 
database20 from February to May 2020, and Premier 
database from February to August 2020), Optum (Eden 
Prairie, MN) deidentified electronic health record 
dataset (Optum-EHR, February to October 2020), 
Tufts Medical Center Clinical Academic Research 
Enterprise Trust (Tufts Research Data Warehouse 
(TRDW), February to May 2020), and the Department 
of Veterans Affairs (VA-OMOP, February to June 
2020). Data for South Korea came from nationwide 
claims recorded in the Health Insurance Review and 
Assessment (HIRA, February to April 2020).21 Inpatient 
electronic health record data from Spain was obtained 
from HM Hospitales (March to April 2020) and 
Hospital del Mar (February to May 2020). Data from 
China was extracted from nine hospitals in Honghu, 
supported by Nanfang Hospital and Southern Medical 
University, and contained full electronic health record 
data (NFHCRD database, January to April 2020). Data 
on drug use in patients receiving intensive care were 
available from IQVIA Hospital CDM, Premier, Optum-
EHR, VA-OMOP, HM Hospitales, and Hospital del Mar. 
Supplementary table 1 provides a detailed description 
of the databases.
study participants
Patients admitted to hospital with a recorded diagnosis 
of covid-19 or a positive polymerase chain reaction test 
result for SARS-CoV-2 between January and December 
2020 were included. A second cohort of patients who 
received intensive care was identified as a subset of 
the former, defined by the initiation of mechanical 
ventilation, extracorporeal membrane oxygenation, 
or tracheostomy. Index dates for the two cohorts were 
the date of admission to hospital and the date intensive 
care started, respectively.
Drugs of interest
We obtained information on all drugs prescribed or 
dispensed during hospital admission. For the study 
of treatments used for covid-19, we assessed all drugs 
included in at least two randomised controlled trials 
according to the covid-19 clinical trial tracker.22 The 
resulting list was circulated to stakeholders with a role 
in drug development and research (eg, key opinion 
leaders, pharmaceutical industry) and drug regulatory 
agencies. All their suggestions were added to the final list 
of medicines under study. We classified the drugs into 
two groups: repurposed drugs—those with alternative 
indications but thought to be efficacious as antivirals; 
and adjuvant drugs—those used to treat pneumonia 
or prevent or treat complications from covid-19.23 
Supplementary table 3 lists the drugs considered. 
For the main results, we focused on drugs covered in 
the living World Health Organization guideline for 
drugs—hydroxychloroquine, lopinavir combined with 
ritonavir, remdesivir, and dexamethasone.7
statistical analysis
We summarise age, sex, and history of medical 
conditions as proportions (the number of participants 
within a category, divided by the total number of 
participants). Supplementary table 2 shows the 
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clinical codes and time windows used to identify 
medical conditions.
Drug use was calculated from the index date 
(admission date or initiation of intensive care) to 30 
days after, or discharge, or death, when these dates 
were available in the database. We calculated use for 
each drug and major drug class. Prevalence of drug use 
was determined by the proportion of participants with 
any active prescription or dispensation of a certain 
drug or drug during hospital admission or the period 
of intensive care. Figure 1 provides a timeline of the 
study. Supplementary figure 1 shows which drugs 
could potentially have been prescribed in the month 
before hospital admission.
All drugs and additional time windows (previous 
year, previous month, and on index date) are 
reported in full and will be updated in a dedica-
ted interactive website (https://data.ohdsi.org/
Covid19CharacterizationCharybdis/) as more data 
become available. All (aggregated) data can be 
downloaded from this website.
To better visualise drug use, we generated rainbow 
plots for each database. These plots display the 
proportion of users of each drug using Anatomical 
Therapeutic Chemical groupings. We also created 
lollipop plots of drug use to show the heterogeneity 
for all selected repurposed and adjuvant drugs 
(see supplementary file). On the basis of drug use 
proportions, we determined the top five most used 
repurposed drugs and top 10 most used adjuvant 
drugs for each database and setting; use of the focused 
medicines are depicted by gauge plots.
We calculated use of the selected drugs by month of 
index date (admission to hospital or start of intensive 
care). To ensure enough time points, we selected 
databases with two or more months of data available 
for each drug. Drug use was plotted for each calendar 
month in the study period. A timeline of selected 
relevant events, such as regulatory decisions or trial 
results for the selected medicines, was added. The 
supplementary appendix provides time series graphs 
for all drugs and groupings.
Patient and public involvement
No funding was available for patient or public 
involvement in this project. Urgency because of the 
covid-19 pandemic and restrictions also prevented 
us from actively involving patients, although the 
Observational Health Data Sciences and Informatics 
community welcomes members of the public to engage 
with its work. No patients were involved in setting the 
research question or the outcome measures. Patients 
were not invited to comment on the study design, not 
consulted to develop patient relevant outcomes or 
interpret the results, and not invited to contribute to 
the writing or editing of this document for readability 
or accuracy.
results
A total of 303 264 patients identified from 11 databases 
were included: 290 131 participants were from the US 
(744 from California, 326 from Massachusetts, 7353 
from New York, 10 951 from US-wide Veterans Affairs, 
and 270 757 from US-wide databases: Premier, IQVIA 
Hospital CDM, and Optum-EHR), 7599 from South 
Korea, 5230 from Spain, and 304 from China, Of these 
303 264 participants, 62 963 (from VA-OMOP, Premier, 
Optum-EHR, IQVIA Hospital CDM, Hospital del Mar, 
and HM Hospitales) received intensive care.
The results of this study are available in an 
interactive website (https://data.ohdsi.org/
Covid19CharacterizationCharybdis/). This website 
contains both the summary results presented here and 
further details, including all drugs and comorbidities 
recorded for the two cohorts.
Table 1 presents the baseline characteristics of 
the patients admitted to hospital with covid-19. 
Supplementary table 4 shows the results for patients 
who received intensive care. Age varied slightly across 
data sources, but most patients were within the age 
Positive test result for, or diagnosis of, covid-19
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or discharge
End of follow-up,
















Active drug use on patients admitted to hospital
Fig 1 | timeline of study
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range 50 to 74 years. The proportion of women was 
40-50% in all settings except South Korea (59%) and 
the VA-OMOP (7%).
A total of 3455 different drugs were administered to 
patients in the month after admission to hospital for 
covid-19 (fig 2). The Anatomical Therapeutic Chemical 
groups consistently seen among the most prescribed 
drugs were anti-infectives for systemic use, treatments 
for blood and blood forming organs, cardiovascular 
system therapies, and drugs for the musculoskeletal 
system.
Table 2 reports the top five most used repurposed 
drugs and table 3 the top 10 most used adjunctive 
drugs in each data source among the drugs of 
interest. Supplementary table 5 shows the results 
for patients who received intensive care. The most 









































 Female 3897 (53) 4483 (59) 1043 (41) 1424 (53) 38 139 (49) 149 (49) 18 359 (50) 74 970 (48) 372 (50) 140 (43) 767 (7)
Age (years):
 0-4 221 (3) 76 (1) 25 (1) <5 2335 (3) <5 367 (1) 1562 (1) 37 (5) 10 (3) <5
 5-9 74 (1) 76 (1) <5 <5 <5 <5 367 (1) <5 7 (1) <5 <5
 10-14 74 (1) 76 (1) <5 <5 <5 <5 367 (1) <5 <5 <5 <5
 15-19 147 (2) 228 (3) <5 <5 778 (1) <5 734 (2) 1562 (1) 15 (2) <5 <5
 20-24 221 (3) 988 (13) 76 (3) <5 1557 (2) 6 (2) 1102 (3) 3124 (2) 15 (2) <5 <5
 25-29 368 (5) 912 (12) 178 (7) 27 (1) 2335 (3) 12 (4) 1469 (4) 4686 (3) 30 (4) 16 (5) 110 (1)
 30-34 441 (6) 380 (5) 153 (6) 27 (1) 3113 (4) 24 (8) 1836 (5) 6247 (4) 37 (5) 16 (5) 110 (1)
 35-39 441 (6) 380 (5) 127 (5) 54 (2) 3113 (4) 24 (8) 1836 (5) 6247 (4) 37 (5) 20 (6) 219 (2)
 40-44 368 (5) 380 (5) 204 (8) 81 (3) 3892 (5) 24 (8) 1836 (5) 7809 (5) 45 (6) 10 (3) 219 (2)
 45-49 294 (4) 608 (8) 204 (8) 134 (5) 4670 (6) 36 (12) 2203 (6) 9371 (6) 45 (6) 20 (6) 329 (3)
 50-54 441 (6) 760 (10) 229 (9) 161 (6) 6227 (8) 40 (13) 2937 (8) 12 495 (8) 52 (7) 13 (4) 657 (6)
 55-59 588 (8) 760 (10) 229 (9) 215 (8) 7784 (10) 46 (15) 3672 (10) 14 057 (9) 82 (11) 36 (11) 876 (8)
 60-64 662 (9) 684 (9) 204 (8) 269 (10) 8562 (11) 27 (9) 3672 (10) 15 619 (10) 82 (11) 39 (12) 1314 (12)
 65-69 662 (9) 380 (5) 153 (6) 295 (11) 8562 (11) 18 (6) 3672 (10) 15 619 (10) 82 (11) 42 (13) 1424 (13)
 70-74 662 (9) 304 (4) 153 (6) 295 (11) 8562 (11) 15 (5) 3305 (9) 15 619 (10) 89 (12) 20 (6) 2300 (21)
 75-79 588 (8) 304 (4) 178 (7) 322 (12) 7005 (9) 18 (6) 2570 (7) 14 057 (9) 60 (8) 20 (6) 1424 (13)
 80-84 515 (7) 152 (2) 127 (5) 269 (10) 9340 (12) 9 (3) 2203 (6) 12 495 (8) 30 (4) 23 (7) 657 (6)
 85-89 294 (4) 152 (2) 153 (6) 269 (10) <5 <5 2937 (8) 14 057 (9) 15 (2) 16 (5) 657 (6)
 90-94 221 (3) 76 (1) 102 (4) 188 (7) <5 <5 <5 4686 (3) <5 7 (2) 438 (4)
 ≥95 74 (1) <5 25 (1) 81 (3) <5 <5 <5 <5 <5 13 (4) 219 (2)
Comorbidities:
 Anaemia 294 (4) 304 (4) — 27 (1) 3113 (4) — 2203 (6) 3124 (2) 74 (10) 13 (4) 876 (8)
 Anxiety disorder 74 (1) 304 (4) — <5 1557 (2) — 1469 (4) 1562 (1) 60 (8) <5 1205 (11)
 Asthma 147 (2) 380 (5) — <5 1557 (2) — 1102 (3) 1562 (1) 52 (7) 7 (2) 219 (2)
 Atrial fibrillation 147 (2) 76 (1) — 27 (1) 1557 (2) — 1469 (4) 1562 (1) 37 (5) 10 (3) 657 (6)
 Chronic liver disease 74 (1) 76 (1) — <5 778 (1) — 367 (1) <5 15 (2) <5 219 (2)
  Chronic obstructive 
pulmonary disease 74 (1) 76 (1)
— 27 (1) 1557 (2) — 1102 (3) 1562 (1) 15 (2) 7 (2) 876 (8)
 Dementia <5 304 (4) — <5 778 (1) — 734 (2) 1562 (1) <5 <5 657 (6)
 Diabetes mellitus 368 (5) 532 (7) — 27 (1) 5448 (7) — 3672 (10) 4686 (3) 67 (9) 16 (5) 1971 (18)
  Gastroesophageal  
reflux disease 147 (2) 836 (11)
— <5 1557 (2) — 1469 (4) 1562 (1) 89 (12) 10 (3) 548 (5)
 Heart disease 735 (10) 380 (5) — 27 (1) 4670 (6) — 4039 (11) 4686 (3) 141 (19) 23 (7) 2081 (19)
 Heart failure 221 (3) 152 (2) — <5 2335 (3) — 1469 (4) 3124 (2) 37 (5) 7 (2) 767 (7)
 Hyperlipidaemia 221 (3) 1216 (16) — 27 (1) 4670 (6) — 3672 (10) 4686 (3) 164 (22) 16 (5) 1424 (13)
  Hypertensive  
disorder 588 (8) 1292 (17)
— 27 (1) 6227 (8) — 5140 (14) 4686 (3) 216 (29) 20 (6) 2300 (21)
 Insomnia 74 (1) 152 (2) — <5 <5 — 367 (1) <5 7 (1) <5 329 (3)
  Ischaemic heart  
disease 147 (2) 152 (2)
— 27 (1) 778 (1) — 1102 (3) 1562 (1) 22 (3) <5 329 (3)
 Low back pain 74 (1) 532 (7) — <5 778 (1) — 734 (2) <5 22 (3) <5 548 (5)
  Malignant neoplastic 
disease 515 (7) 152 (2)
— 27 (1) 1557 (2) — 1469 (4) 1562 (1) 201 (27) 10 (3) 767 (7)
 Osteoarthritis of hip <5 <5 — <5 <5 — <5 <5 22 (3) <5 <5
 Osteoarthritis of knee 74 (1) 152 (2) — <5 <5 — 367 (1) <5 37 (5) <5 219 (2)
  Peripheral vascular 
disease 74 (1) 228 (3)
— <5 778 (1) — 734 (2) 1562 (1) 7 (1) 16 (5) 329 (3)
 Renal impairment 294 (4) 76 (1) — 27 (1) 3113 (4) — 2570 (7) 3124 (2) 89 (12) <5 1314 (12)
 Venous thrombosis <5 <5 — <5 <5 — 367 (1) <5 15 (2) 13 (4) 110 (1)
 Viral hepatitis <5 76 (1) — <5 <5 — <5 <5 15 (2) <5 110 (1)
Mortality 735 (10) 228 (3) 356 (14) — 10897 (14) <5 1469 (4) 1562 (1) 7 (1) 33 (10) 1643 (15)
CUIMC=Columbia University Irving Medical Center; HIRA=Health Insurance Review and Assessment; OMOP=Observational Medical Outcomes Partnership; Optum-EHR=Optum deidentified 
electronic health record dataset; STARR=STAnford medicine Research data Repository; TRDW=Tufts Research Data Warehouse; VA=Veterans Affairs.
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Blood and blood forming organs
Cardiovascular system
Dermatologicals





Systemic hormonal preparations, excluding sex hormones and insulins
Uncategorised
Various
Alimentary tract and metabolism
Anti-infectives for systemic use
Antiparasitic products, insecticides, and repellents
Fig 2 | Percentage of any use (one day or more) of all drugs (rainbow plot) on days 0 to 30 after hospital admission in patients with a positive 
test result for or diagnosis of covid-19. cuiMc=columbia university irving Medical center; Hira=Health insurance review and assessment; 
OMOP=Observational Medical Outcomes Partnership; Optum-eHr=Optum deidentified electronic health record dataset; starr=stanford medicine 
research data repository; trDW=tufts research Data Warehouse; va=veterans affairs
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popular antivirals were hydroxychloroquine (from 
14% in VA-OMOP, US, to 85% in HM Hospitales, 
Spain), lopinavir-ritonavir (from 0.3% in VA-OMOP to 
50% in HM Hospitales), oseltamivir (0.5% in Optum-
EHR, US, to 13% in NFHCRD, China), and remdesivir 
(7.7% in CUIMC, US, and 7.3% in IQVIA Hospital 
CDM, US). China used different products: umifenovir, 
prescribed to 78% of patients admitted to hospital, 
ribavirin (21%), and chloroquine (12%). Commonly 
used adjunctive treatments included antithrombo-
tics, corticosteroids, antibiotics, metformin, vitamin 
supplements (C and D), antihypertensives, H2 receptor 
antagonists, and interleukin inhibitors.
Figure 3 shows the proportion of users of each 
of the drugs of interest both in patients admitted to 
hospital and in patients receiving intensive care, 
for each database (also see supplementary figures 
2-5). Hydroxychloroquine was the most used drug, 
but this varied greatly, ranging from <2% in China 
to 85% in Spain (HM Hospitales). Chloroquine was 
used in China (11.5%). Dexamethasone was widely 
used in the US (20-54%). Both drugs had increased 
use in patients receiving intensive care services, 
except for dexamethasone in HM Hospitales. Use 
of azithromycin varied, ranging from 58% in HM 
Hospitales to 5% in China. Lopinavir-ritonavir was 
used in South Korea, Spain, and China. Tocilizumab 
was used in some US settings (5-10% of patients) and 
in HM Hospitales. The use of adjunctive treatments 
increased substantially among patients who received 
intensive care, with the greatest augmentation seen 
for systemic corticosteroids, famotidine, heparin, and 
tocilizumab.
Supplementary figure 1 shows drug use before 
and during hospital admission. All the repurposed 
drugs were associated with increased drug use during 
hospital admission. Dexamethasone, corticosteroids, 
azithromycin, and tocilizumab also showed higher 
use during hospital admission compared with before 
hospital admission.
The management of covid-19 has changed sub-
stantially over time (see supplementary figure 
6 and fig 4, fig 5, fig 6, and fig 7). The trends in 
hydroxychloroquine use show a rapid increase during 
February and March 2020, followed by a similarly 
rapid decline in May that continued until the end of 
the year. The upward trend coincided with reports of 
in vitro and in vivo activity and regulatory approval 
of hydroxychloroquine (fig 4). The downward trend 
coincided with reports on safety concerns and of lack 
of effectiveness. Dexamethasone was scarcely used in 
the first few months of the pandemic, except in the 
US (STARR-OMOP database). After the Recovery trial 
report in June 2020 showed a reduction in mortality 
associated with dexamethasone, use increased rapidly 
and then stabilised. Lopinavir-ritonavir was only used 
table 2 | top five most used repurposed drugs in each data source in patients admitted to hospital with covid-19 on days 0 to 30 after hospital 




































1 HCQ (22.3) L-R (34.9) HCQ (85.1) HCQ (40.2) AZM (47.4) UMF (78.3) AZM (37.0) AZM (46.6) AZM (8.7) AZM (28.5) AZM (33.0)
2 AZM (21.4) HCQ (27.4) AZM (57.9) AZM (7.9) HCQ (9.3) RBV (21.1) HCQ (20.5) HCQ (22.8) HCQ (3.2) HCQ (19.9) HCQ (13.5)
3 RMD (7.7) AZM (13.7) L-R (50.5) L-R (4.4) RMD (7.3) OST (13.2) L-R (1.2) OST (0.5) OST (1.1) OST (<1.5) OST (0.7)
4 OST (0.9) PIFN (0.4) OST (5.8) OST (<0.2) IVM (0.9) CQ (11.5) OST (0.5) L-R (0.4) ICN (0.7) L-R (<1.5) IVM (0.3)
5 IVM (0.3) OST (0.4) CQ (0.3) — OST (0.5) L-R (7.2) IVM (0.2) — RBV (<0.7) — L-R (0.3)
CUIMC=Columbia University Irving Medical Center; HIRA=Health Insurance Review and Assessment; OMOP=Observational Medical Outcomes Partnership; Optum-EHR=Optum deidentified 
electronic health record dataset; STARR=STAnford medicine Research data Repository; TRDW=Tufts Research Data Warehouse; VA=Veterans Affairs; HCQ=hydroxychloroquine; AZM=azithromycin; 
RMD=remdesivir; OST=oseltamivir; IVM=ivermectin; L-R=lopinavir-ritonavir; PIFN=pegylated interferon alfa-2a; CQ=chloroquine; UMF=umifenovir; RBV=ribavirin; ICN=itraconazole.
table 3 | top 10 most used adjunctive drugs in each data source on days 0 to 30 after hospital admission. Data are treatment (percentage of patients 







































1 Vit D (88.1) Fluoro (24.7) Bemi (82.0) Enox (52.2) Vit D (84.8) Fluoro (63.8) Enox (53.7) Enox (62.1) CS (66.7) Enox (58.3) Vit D (95.3)
2 Enox (54.0) H2RA (16.4) Ceft (61.5) Vit D (24.1) Enox (55.5) Vit C (58.6) CS (46.5) CS (38.2) Hep (50.7) Hep (51.2) Enox (59.7)
3 CS (41.4) Stat (13.5) CS (44.4) CS (23.1) Ceft (50.2) CS (40.8) Ceft (37.6) Stat (33.3) α1b (38.3) Ceft (40.5) Stat (58.3)
4 Hep (38.1) ARBs (13.1) Fluoro (23.8) Ceft (15.7) CS (49.3) Ig (22.0) Stat (33.0) Asp (27.2) Enox (32.8) Stat (36.2) CS (40.9)
5 Stat (32.2) CS (10.4) Tocil (17.1) ACEI (9.2) Hep (28.9) Amox (15.1) Vit D (30.4) H2RA (24.5) Asp (28.6) CS (34.0) Asp (40.7)
6 Asp (27.6) Vit C (9.7) Asp (12.8) ARB (4.5) Stat (25.7) ARB (8.9) Asp (28.1) Vit C (21.5) Stat (28.4) Asp (23.6) Ceft (34.2)
7 Ceft (26.0) Met (8.3) Stat (12.7) Met (3.0) H2RA (23.0) Met (6.9) Hep (28.0) DfXaI (12.6) H2RA (23.8) Vit D (17.8) Hep (34.1)
8 H2RA (25.1) Ceft (8.2) ARB (12.6) Stat (0.9) Asp (21.1) Stat (4.6) H2RA (22.5) α1b (12.0) Ceft (13.3) H2RA (17.2) ACEI (25.9)
9 α1b (12.8) Vit D (8.1) ACEI (12.5) Asp (0.7) Vit C (19.9) Ceft (3.6) Vit C (15.9) ACEI (11.0) Tran (12.1) α1b (16.3) DfXaI (18.8)
10 ACEI (10.5) DPP-4I (4.8) α1b (3.5) Hep (0.6) α1b (10.0) Enox (2.0) ACEI (15.4) ARB (8.5) Fluoro (9.9) ACEI (9.5) Met (18.6)
CUIMC=Columbia University Irving Medical Center; HIRA=Health Insurance Review and Assessment; OMOP=Observational Medical Outcomes Partnership; Optum-EHR=Optum deidentified 
electronic health record dataset; STARR=STAnford medicine Research data Repository; TRDW=Tufts Research Data Warehouse; VA=Veterans Affairs; Vit=vitamin; Enox=enoxaparin; 
CS=corticosteroids; Hep=heparin; Stat=statins; Asp=aspirin; Ceft=ceftriaxone; H2RA=H2 receptor antagonist; α1b=α1 blockers; ACEI=angiotensin converting enzyme inhibitors; 
Fluoro=fluoroquinolones; ARB=angiotensin receptor blockers; Met=metformin; DDP-4I=dipeptidyl peptidase-4 inhibitors; Bemi=bemiparin; Tocil=tocilizumab; Ig=immunoglobulins; 
Amox=amoxicillin; DfXaI=direct factor Xa inhibitors; Tran=tranexamic acid.
copyright.
 on 18 M














J: first published as 10.1136/bm






the bmj | BMJ 2021;373:n1038 | doi: 10.1136/bmj.n1038 7
at the start of the pandemic in South Korea and Spain, 
with a downward trend over time. Remdesivir was only 
recorded in CUIMC and IQVIA Hospital CDM, and it 
showed a slight upward trend from June onwards.
discussion
This study reports on the use of repurposed and 
adjunctive drugs for the treatment of patients admitted 














































Fig 3 | Percentage of any use (one day or more) of selected drugs on days 0 to 30 after hospital admission in patients with a positive test result for 
or diagnosis of covid-19. cuiMc=columbia university irving Medical center; Hira=Health insurance review and assessment; OMOP=Observational 
Medical Outcomes Partnership; Optum-eHr=Optum deidentified electronic health record dataset; starr=stanford medicine research data 
repository; trDW=tufts research Data Warehouse; va=veterans affairs
South Korea
February 2020








February March April May June July August September October November December
HIRA (n=7599)
HM Hospitales (n=2544)
Hospital del Mar (n=2686)




9 March    Yao et al - Hydroxychloroquine shows superior in vitro activity to chloroquine
19 March    President Trump promotes hydroxychloroquine in press conference
20 March    Gautret et al - Open-label non-randomized clinical trial shows effectiveness
28 March    US Food and Drug Administration issues an emergency use authorisation
31 March    Chen et al - Preprint of a randomised controlled trial suggests that hydroxychloroquine reduces time to clinical recovery
April 2020
10 April    Lane et al - Observational data show that azithromycin combined with hydroxychloroquine may increase
                   cardiovascular mortality
24 April    FDA and European Medicines Agency caution against the use of hydroxychloroquine owing to potential
                   heart rhythm problems
May 2020
7 May    Geleris et al - Lack of effectiveness of hydroxychloroquine on observational data
28 May    WHO halts hydroxychloroquine arm of Solidarity trial
June 2020
8 June    Recovery trial press note shows that hydroxychloroquine has no effect on
                 covid-19










Fig 4 | time trends in hydroxychloroquine use on days 0 to 30 after hospital admission in patients with a positive test result for or diagnosis of 
covid-19 by month. cuiMc=columbia university irving Medical center; Hira=Health insurance review and assessment; OMOP=Observational 
Medical Outcomes Partnership; Optum-eHr=Optum deidentified electronic health record dataset; starr=stanford medicine research data 
repository; va=veterans affairs
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intensive care, as recorded in electronic medical 
records and claims data across three continents. A total 
of 303 264 patients were admitted to hospital of whom 
62 963 received intensive care for covid-19 in the US, 
South Korea, Spain, and China.
We observed high heterogeneity in the use of 
repurposed drugs, with great variability in the use 
of hydroxychloroquine both geographically and 
temporally. Similar trends were observed for azithro-
mycin. Use of antiretrovirals also varied greatly, with 
lopinavir-ritonavir use ranging from 0% in the US (VA-
OMOP) to 35% in South Korea (HIRA), and highest at 
50% in Spain (HM Hospitales).
Adjunctive treatments have been extensively used 
for the prevention of or treatment for complications 
from covid-19, including antibiotics, anticoagulants, 
corticosteroids, vitamin D supplements, and, to a 
lesser degree, antihypertensives, antacids, statins, 
and metformin. The use of adjunctive drugs increased 
among patients who required intensive care.
Hydroxychloroquine has been given much publicity 
since the start of the pandemic. Its use has been 
supported or endorsed on the basis of misleading 
evidence from flawed but heavily publicised 
studies.24-26 Numerous randomised controlled trials 
have, however, shown no benefit. The Recovery 
trial of 1542 hospital patients with covid-19 treated 
with hydroxychloroquine showed no effects on 28 
day mortality compared with usual care.27 Another 








February March April May June July August September October November December
October 2020
15 Oct    Solidarity trial preprint shows no effect of
                  lopinavir-ritonavir on mortality, ventilation,









Hospital del Mar (n=2686)







29 June    Recovery trial press note shows no clinical benefit from the
                   use of lopinavir-ritonavir in patients admitted to hospital
Fig 6 | time trends combined lopinavir and ritonavir use on days 0 to 30 after hospital admission in patients with a positive test result for 
or diagnosis of covid-19 by month. cuiMc=columbia university irving Medical center; Hira=Health insurance review and assessment; 
OMOP=Observational Medical Outcomes Partnership; Optum-eHr=Optum deidentified electronic health record dataset; va=veterans affairs
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22 May    Beigel et al - ACTT-1 trial shows remdesivir shortens time to recovery in patients admitted to hospital
October 2020
15 Oct    Solidarity trial preprint shows no effect of
                  remdesivir on mortality, ventilation, or






Fig 5 | time trends in remdesivir use on days 0 to 30 after hospital admission in patients with a positive test result for or diagnosis of covid-19 by 
month. actt-1=adaptive cOviD-19 treatment trial 1; cuiMc=columbia university irving Medical center
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hydroxychloroquine as post-exposure prophylaxis 
in 821 asymptomatic participants but was found not 
to prevent covid-19 illness after high or moderate 
exposure to covid-19.28 Hydroxychloroquine use 
increased rapidly when these studies appeared and 
were heavily publicised and politically endorsed. 
During March and April 2020, more than 50% of 
patients admitted to hospital with covid-19 were 
prescribed hydroxychloroquine. After several papers 
and regulatory agencies warned about potential side 
effects, especially when hydroxychloroquine was 
combined with azithromycin, the use of hydroxy-
chloroquine began to decline. Finally, after the 
Solidarity trial halted its hydroxychloroquine arm and 
the Recovery trial presented definitive evidence against 
the use of hydroxychloroquine, the FDA revoked its 
approval for emergency use and prescribing decreased 
to almost 0% in all settings.29 30
We found that azithromycin, a macrolide antibiotic 
with alleged antiviral efficacy against covid-19, was 
also widely prescribed. Although several guidelines in 
2020 recommended the use of empirical antimicrobial 
treatment, not all advocated its use.31 In mid-December 
the Recovery trial showed no benefit from azithromycin 
in patients admitted to hospital with covid-19.32 We 
were not able to see the impact in trends as we only 
had data until December 2020.
Combined use of the protease inhibitors lopinavir 
and ritonavir was high in South Korea and Spain, with 
the other databases showing a much lower use. This 
was consistent with Korean and Spanish guidelines at 
the time of our study, which recommended protease 
inhibitors as antiviral treatments,11 12 probably based 
on in vitro studies.33 The Recovery and Solidarity trials 
confirmed the lack of efficacy of lopinavir-ritonavir 
compared with usual care.29 30
Remdesivir, another highly publicised antiviral, was 
only used in two databases, and in less than 25% of 
patients. Umifenovir in China was the most prescribed 
repurposed drug, consistent with Chinese guidelines 
and research.34 35
Adjunctive drugs used to prevent covid-19 or treat 
complications differed noticeably worldwide. Use of 
corticosteroids ranged from about 10% of admitted 
patients in South Korea (HIRA) to 67% of patients in 
Stanford (California, US).
Before results were available from the Recovery trial, 
there was a wide debate on whether corticosteroids 
have a role in mitigating inflammatory organ 
injury.36 37 Most clinical guidelines did not recommend 
the use of corticosteroids to treat covid-19,31 with 
notable exceptions.24 38 The use of dexamethasone 
was low in almost all settings in our study until June 
2020, when the Recovery trial showed its efficacy in 
reducing death in patients admitted to hospital with 
severe covid-19 related disease receiving respiratory 
support.39 Corticosteroid use in general appeared to 
increase slowly during the study period.
The use of anticoagulants in our study was higher 
than expected. Heparin use was widely prescribed 
in the US and Spain, but not in China or South 
Korea. Severe covid-19 has been associated with a 
coagulopathy, which when untreated leads to poor 
clinical outcomes.40 Although several randomised 
controlled trials are ongoing to evaluate the value of 
anticoagulation in patients with covid-19, interim 
guidelines recommend the use of anticoagulants 
for prophylaxis against thromboembolism.12 41 The 
use of antibiotics also varied widely, as did the use 
of statins. Traditional Chinese medicines were not 
widely prescribed (<10% recorded in NFHCRD; see 
supplementary table 6).
The observed heterogeneity and rapid changes 
in drug use go hand in hand with the infodemic 
associated with covid-19. We have shown how the 
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Premier (n=156 187) June 2020
16 June    Recovery trial press note shows that dexamethasome reduces death by
                   up to one third in patients admitted to hospital with severe respiratory
                   disease
Fig 7 | time trends in dexamethasone use on days 0 to 30 after hospital admission in patients with a positive test result for or diagnosis of covid-19 
by month. cuiMc=columbia university irving Medical center; Hira=Health insurance review and assessment; OMOP=Observational Medical 
Outcomes Partnership; Optum-eHr=Optum deidentified electronic health record dataset; starr=stanford medicine research data repository; 
va=veterans affairs
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endorsements are aligned with changes in practice 
patterns and potentially influence the decisions of 
regulators.42 Retrospective evaluation of management 
and treatment practices during the pandemic are 
necessary43 to safeguard against the increase in use of 
unproven and potentially harmful treatments, during 
future waves of the pandemic and public health crises.
limitations of this study
Our study was based on routinely collected real world 
data (electronic health records and claims data), with 
the potential for misclassification of disease and 
treatments. We only included patients with a clinical 
diagnosis of covid-19 or a positive polymerase chain 
reaction test result during hospital admissions or 21 
days previously; therefore, patients without a coded 
diagnosis would have been excluded even if they were 
suspected of having covid-19. The number of patients 
with covid-19 might also be underreported in clinical 
settings with scarce testing resources, especially when 
volumes of patients are high. In addition, medical 
conditions might be underreported because the 
absence of a medical code for the disease is interpreted 
as absence of the disease. Exposure misclassification 
is also possible; participating data sources varied in 
how drugs were captured (eg, hospital billing records, 
prescription orders, dispensing data).
Estimates for drug use on the date of hospital 
admission are particularly sensitive to misclassification 
and could conflate baseline concomitant drug history 
with immediate treatment on admission. We further 
explored this (see supplemental figure 1) and found 
that the drugs we focused on were not typically used 
before hospital admission according to the data 
sources.
We did not differentiate between drugs prescribed 
on the day of hospital admission from those in 
the following days or in the context of worsening 
disease. This could also mean that some drugs used 
at discharge (or those prescribed after discharge) 
could have appeared as being prescribed to patients 
during hospital admission. To avoid this, we censored 
on discharge when this information was available. 
Additionally, in most of the databases where this date 
was not available, only inpatient data were provided, 
so these drugs would not be recorded.
Another limitation of our study was the lack of 
information on dose and duration of drug treatments. 
These are important factors that would have added 
value to our understanding of the trends in prescribing, 
especially among those in high risk groups or those 
with greater susceptibility to drug related adverse 
events.
Although our study adds valuable information to 
the understanding of prescribing patterns for covid-19 
in 2020, it only provides a snapshot of drug use in 
clinical practice. As new evidence continually emerges 
over time, drug use in covid-19 is likely to evolve 
rapidly. Although possibly not representative of global 
treatment patterns, our data provide a good oversight of 
inpatient treatment for covid-19 in real world practice 
settings during 2020. Our study cohorts included both 
academic hospitals (eg, at Columbia University and 
Stanford University) as well as nationwide data sources 
and including other less specialised treatment centres 
(eg, HIRA, IQVIA Hospital CDM). Owing to the varied 
settings we decided not to provide drug use by country 
or overall because it would not be representative of the 
underlying populations.
conclusions
Great interest has been shown in the safety and efficacy 
of drugs used to treat covid-19, but little evidence 
exists on the prescribing patterns for repurposed and 
adjuvant drugs in routine clinical practice. Our study 
shows how unproven drug treatments were used 
during the first months of the pandemic, with great 
heterogeneity between centres, and that they were 
quickly replaced by proven treatments.
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